Total revenues rose 23% YoY for Q2FY23 at Rs 2,384 crore compared to Rs 1,945 crore in Q2FY22 ...More

Total revenues rose 23% YoY for Q2FY23 at Rs 2,384 crore compared to Rs 1,945 crore in Q2FY22 ...Less

EBITDA for the quarter increased by 68% YoY to Rs 900 crore, representing an EBITDA margin of 25% versus ...More

EBITDA for the quarter increased by 68% YoY to Rs 900 crore, representing an EBITDA margin of 25% versus 22% in the same period last year. The gross R&D spends grew 10% YoY to Rs 278 crore in Q2FY24. ...Less

According to ET Now poll, the company is likely to report a net profit of Rs 95.8 crore, up 7 per cent, a ...More

According to ET Now poll, the company is likely to report a net profit of Rs 95.8 crore, up 7 per cent, as compared to a net profit of Rs 89.6 crore in the corresponding quarter last fiscal. ...Less

Biocon shares: The board approved a hike in the company’s authorised share capital from Rs 625 crore to R ...More

Biocon shares: The board approved a hike in the company’s authorised share capital from Rs 625 crore to Rs 700 crore, along with a corresponding amendment to the capital clause in its Memorandum of Association. ...Less

Biocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 c ...More

Biocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 crore in Q3FY25. In comparison, the company had posted a net profit of Rs 660 crore in Q3FY24, boosted by an exceptional item of Rs 566 crore. ...Less